NASDAQ:WVE - WAVE Life Sciences Stock Price, Price Target & More

$43.50 +1.50 (+3.57 %)
(As of 04/22/2018 12:25 PM ET)
Previous Close$43.50
Today's Range$42.00 - $43.75
52-Week Range$15.15 - $55.95
Volume111,250 shs
Average Volume146,439 shs
Market Capitalization$1.22 billion
P/E Ratio-11.30
Dividend YieldN/A
Beta0.67

About WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences logoWave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388

Debt

Debt-to-Equity Ratio0.02%
Current Ratio7.67%
Quick Ratio7.67%

Price-To-Earnings

Trailing P/E Ratio-11.30
Forward P/E Ratio-12.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.70 million
Price / Sales329.07
Cash FlowN/A
Price / CashN/A
Book Value$5.03 per share
Price / Book8.65

Profitability

EPS (Most Recent Fiscal Year)($3.85)
Net Income$-102,030,000.00
Net Margins-2,754.73%
Return on Equity-66.73%
Return on Assets-53.57%

Miscellaneous

Employees168
Outstanding Shares27,990,000

How to Become a New Pot Stock Millionaire

WAVE Life Sciences (NASDAQ:WVE) Frequently Asked Questions

What is WAVE Life Sciences' stock symbol?

WAVE Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How were WAVE Life Sciences' earnings last quarter?

WAVE Life Sciences (NASDAQ:WVE) released its quarterly earnings data on Monday, March, 12th. The company reported ($1.09) EPS for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.09. The business earned $1.68 million during the quarter, compared to analyst estimates of $0.63 million. WAVE Life Sciences had a negative net margin of 2,754.73% and a negative return on equity of 66.73%. View WAVE Life Sciences' Earnings History.

When is WAVE Life Sciences' next earnings date?

WAVE Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for WAVE Life Sciences.

What price target have analysts set for WVE?

5 analysts have issued 12 month price objectives for WAVE Life Sciences' stock. Their predictions range from $40.00 to $65.00. On average, they anticipate WAVE Life Sciences' stock price to reach $53.40 in the next year. View Analyst Ratings for WAVE Life Sciences.

Who are some of WAVE Life Sciences' key competitors?

Who are WAVE Life Sciences' key executives?

WAVE Life Sciences' management team includes the folowing people:
  • Dr. Paul B. Bolno M.D., MBA, Pres, CEO & Director (Age 44)
  • Mr. Keith C. Regnante MBA, Chief Financial Officer (Age 48)
  • Mr. Ken Takanashi MBA., CPA, Corp. Sec. & Director (Age 54)
  • Dr. Michael A. Panzara M.D., MPH, Franchise Lead of Neurology (Age 51)
  • Dr. Takeshi Wada, Scientific Advisor (Age 56)

Has WAVE Life Sciences been receiving favorable news coverage?

Headlines about WVE stock have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. WAVE Life Sciences earned a news sentiment score of -0.02 on Accern's scale. They also assigned news headlines about the company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are WAVE Life Sciences' major shareholders?

WAVE Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%) and KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%). Company insiders that own WAVE Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Ra Capital Management, Llc. View Institutional Ownership Trends for WAVE Life Sciences.

How do I buy shares of WAVE Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is WAVE Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $43.50.

How big of a company is WAVE Life Sciences?

WAVE Life Sciences has a market capitalization of $1.22 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. WAVE Life Sciences employs 168 workers across the globe.

How can I contact WAVE Life Sciences?

WAVE Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]


MarketBeat Community Rating for WAVE Life Sciences (WVE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about WAVE Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

WAVE Life Sciences (NASDAQ:WVE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for WAVE Life Sciences in the last 12 months. Their average twelve-month price target is $53.40, suggesting that the stock has a possible upside of 22.76%. The high price target for WVE is $65.00 and the low price target for WVE is $40.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.40$53.40$41.60$40.00
Price Target Upside: 22.76% upside28.67% upside68.08% upside75.05% upside

WAVE Life Sciences (NASDAQ:WVE) Consensus Price Target History

Price Target History for WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ:WVE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018MizuhoBoost Price TargetBuy -> Buy$34.00 -> $65.00HighView Rating Details
3/13/2018Leerink SwannLower Price TargetOutperform -> Outperform$64.00 -> $62.00HighView Rating Details
3/9/2018SunTrust BanksBoost Price TargetBuy$60.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$42.00 -> $40.00LowView Rating Details
6/9/2017JMP SecuritiesReiterated RatingOutperform$40.00LowView Rating Details
3/27/2017HC WainwrightReiterated RatingBuyHighView Rating Details
(Data available from 4/22/2016 forward)

Earnings

WAVE Life Sciences (NASDAQ:WVE) Earnings History and Estimates Chart

Earnings by Quarter for WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ:WVE) Earnings Estimates

2018 EPS Consensus Estimate: ($3.81)
2019 EPS Consensus Estimate: ($2.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.07)($0.86)($0.94)
Q2 20183($1.07)($0.89)($0.95)
Q3 20183($1.08)($0.83)($0.94)
Q4 20183($1.13)($0.85)($0.98)
Q1 20191($0.62)($0.62)($0.62)
Q2 20191($0.65)($0.65)($0.65)
Q3 20191($0.68)($0.68)($0.68)
Q4 20191($0.72)($0.72)($0.72)

WAVE Life Sciences (NASDAQ WVE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
3/12/2018Q4 2017($1.00)($1.09)$0.63 million$1.68 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.97)($0.94)$0.77 million$0.68 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.78)($0.92)$0.73 million$0.68 millionViewN/AView Earnings Details
5/10/20173/31/2017($0.77)($0.89)$0.80 million$0.68 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.80)($0.79)$0.56 million$0.68 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.53)($0.75)$0.50 million$0.39 millionViewN/AView Earnings Details
8/15/2016Q2($0.3730)($0.51)$0.42 millionViewN/AView Earnings Details
5/16/2016Q1($0.3730)($0.36)ViewN/AView Earnings Details
3/30/2016Q4($0.28)($0.47)ViewN/AView Earnings Details
12/17/2015Q3 2015($0.29)($0.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

WAVE Life Sciences (NASDAQ:WVE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

WAVE Life Sciences (NASDAQ WVE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 53.00%
Institutional Ownership Percentage: 79.38%
Insider Trading History for WAVE Life Sciences (NASDAQ:WVE)
Insider Trading History for WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences (NASDAQ WVE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2018Chris FrancisInsiderSell21,639$55.40$1,198,800.60View SEC Filing  
2/16/2018Keith RegnanteCFOSell316$51.85$16,384.60View SEC Filing  
2/16/2018Michael A PanzaraInsiderSell511$52.10$26,623.10View SEC Filing  
1/23/2018Chandra VargeeseInsiderSell2,000$40.00$80,000.00View SEC Filing  
11/22/2017Chandra VargeeseInsiderSell1,500$35.00$52,500.00View SEC Filing  
11/14/2017Ra Capital Management, LlcDirectorBuy423,398$23.34$9,882,109.32View SEC Filing  
9/18/2017Masaharu TanakaDirectorSell20,747$24.21$502,284.87View SEC Filing  
7/12/2017Michael A PanzaraInsiderSell7,414$16.67$123,591.3815,336View SEC Filing  
3/29/2017Masaharu TanakaDirectorSell433,825$24.91$10,806,580.75View SEC Filing  
6/15/2016Gregory L VerdineDirectorSell52,000$16.70$868,400.00150,079View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

WAVE Life Sciences (NASDAQ WVE) News Headlines

Source:
DateHeadline
Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntingtons Disease at the 2018 American Academy of Neurology Annual MeetingWave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 17 at 9:53 AM
Wave Life Sciences (WVE) Upgraded by ValuEngine to HoldWave Life Sciences (WVE) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 12 at 10:18 PM
Wave Life Sciences Ltd (WVE) Given Average Recommendation of "Buy" by BrokeragesWave Life Sciences Ltd (WVE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 5:59 PM
Wave Life Sciences teams up with Deep Genomics to develop neuromuscular therapies; shares up 2%Wave Life Sciences teams up with Deep Genomics to develop neuromuscular therapies; shares up 2%
seekingalpha.com - April 10 at 4:13 PM
Zacks: Brokerages Expect Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $6.59 MillionZacks: Brokerages Expect Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $6.59 Million
www.americanbankingnews.com - April 7 at 1:47 AM
Wave Life Sciences to Present at Upcoming Investor ConferencesWave Life Sciences to Present at Upcoming Investor Conferences
finance.yahoo.com - April 6 at 10:19 AM
-$0.94 Earnings Per Share Expected for Wave Life Sciences Ltd (WVE) This Quarter-$0.94 Earnings Per Share Expected for Wave Life Sciences Ltd (WVE) This Quarter
www.americanbankingnews.com - April 5 at 11:10 PM
BidaskClub Lowers Wave Life Sciences (WVE) to HoldBidaskClub Lowers Wave Life Sciences (WVE) to Hold
www.americanbankingnews.com - March 30 at 2:18 PM
Wave Life Sciences Ltd (WVE) Expected to Post Quarterly Sales of $6.59 MillionWave Life Sciences Ltd (WVE) Expected to Post Quarterly Sales of $6.59 Million
www.americanbankingnews.com - March 22 at 10:37 AM
Wave Life Sciences (WVE) Given New $65.00 Price Target at MizuhoWave Life Sciences (WVE) Given New $65.00 Price Target at Mizuho
www.americanbankingnews.com - March 19 at 8:03 AM
Wave Life Sciences Ltd (WVE) Given Consensus Rating of "Buy" by AnalystsWave Life Sciences Ltd (WVE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 18 at 5:37 PM
Leerink Swann Lowers Wave Life Sciences (WVE) Price Target to $62.00Leerink Swann Lowers Wave Life Sciences (WVE) Price Target to $62.00
www.americanbankingnews.com - March 18 at 11:32 AM
WAVE Life Sciences (WVE) PT Lowered to $62 at Leerink PartnersWAVE Life Sciences (WVE) PT Lowered to $62 at Leerink Partners
www.streetinsider.com - March 15 at 10:44 AM
Leerink Swann Comments on Wave Life Sciences Ltds Q1 2018 Earnings (WVE)Leerink Swann Comments on Wave Life Sciences Ltd's Q1 2018 Earnings (WVE)
www.americanbankingnews.com - March 15 at 6:35 AM
Analysts Issue Forecasts for Wave Life Sciences Ltds Q1 2018 Earnings (WVE)Analysts Issue Forecasts for Wave Life Sciences Ltd's Q1 2018 Earnings (WVE)
www.americanbankingnews.com - March 15 at 6:35 AM
Wave Life Sciences Ltd (WVE) Expected to Earn Q1 2018 Earnings of ($1.07) Per ShareWave Life Sciences Ltd (WVE) Expected to Earn Q1 2018 Earnings of ($1.07) Per Share
www.americanbankingnews.com - March 15 at 6:28 AM
Equities Analysts Set Expectations for Wave Life Sciences Ltds Q1 2019 Earnings (WVE)Equities Analysts Set Expectations for Wave Life Sciences Ltd's Q1 2019 Earnings (WVE)
www.americanbankingnews.com - March 14 at 12:30 PM
Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business UpdateWave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 12 at 4:16 PM
Wave Life Sciences (WVE) PT Raised to $60.00Wave Life Sciences (WVE) PT Raised to $60.00
www.americanbankingnews.com - March 9 at 8:32 PM
Leerink Swann Reaffirms "Outperform" Rating for Wave Life Sciences (WVE)Leerink Swann Reaffirms "Outperform" Rating for Wave Life Sciences (WVE)
www.americanbankingnews.com - March 7 at 10:59 AM
Wave Life Sciences Ltd to Post FY2017 Earnings of ($3.82) Per Share, Leerink Swann Forecasts (WVE)Wave Life Sciences Ltd to Post FY2017 Earnings of ($3.82) Per Share, Leerink Swann Forecasts (WVE)
www.americanbankingnews.com - March 7 at 7:26 AM
OvaScience (OVAS) versus Wave Life Sciences (WVE) Critical ContrastOvaScience (OVAS) versus Wave Life Sciences (WVE) Critical Contrast
www.americanbankingnews.com - March 5 at 3:08 AM
Wave Life Sciences Ltd (WVE) Position Lowered by Emory UniversityWave Life Sciences Ltd (WVE) Position Lowered by Emory University
www.americanbankingnews.com - March 4 at 2:59 PM
 Brokerages Anticipate Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $630,000.00 Brokerages Anticipate Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $630,000.00
www.americanbankingnews.com - March 4 at 2:38 AM
BidaskClub Downgrades Wave Life Sciences (WVE) to BuyBidaskClub Downgrades Wave Life Sciences (WVE) to Buy
www.americanbankingnews.com - March 3 at 6:14 PM
Spark Investment Management LLC Invests $1.41 Million in Wave Life Sciences Ltd (WVE)Spark Investment Management LLC Invests $1.41 Million in Wave Life Sciences Ltd (WVE)
www.americanbankingnews.com - March 3 at 12:36 PM
Research Analysts Offer Predictions for Wave Life Sciences Ltds Q1 2018 Earnings (WVE)Research Analysts Offer Predictions for Wave Life Sciences Ltd's Q1 2018 Earnings (WVE)
www.americanbankingnews.com - February 23 at 8:24 AM
Q1 2018 EPS Estimates for Wave Life Sciences Ltd Increased by Leerink Swann (WVE)Q1 2018 EPS Estimates for Wave Life Sciences Ltd Increased by Leerink Swann (WVE)
www.americanbankingnews.com - February 23 at 8:24 AM
Wave Life Sciences teams up with Takeda to develop CNS treatmentsWave Life Sciences teams up with Takeda to develop CNS treatments
seekingalpha.com - February 22 at 4:19 PM
Wave Life Sciences Ltd (WVE) Forecasted to Post FY2022 Earnings of ($3.54) Per ShareWave Life Sciences Ltd (WVE) Forecasted to Post FY2022 Earnings of ($3.54) Per Share
www.americanbankingnews.com - February 22 at 4:14 PM
Wave Life Sciences Ltd (WVE) CFO Keith Regnante Sells 316 SharesWave Life Sciences Ltd (WVE) CFO Keith Regnante Sells 316 Shares
www.americanbankingnews.com - February 21 at 9:38 PM
Insider Selling: Wave Life Sciences Ltd (WVE) Insider Sells 511 Shares of StockInsider Selling: Wave Life Sciences Ltd (WVE) Insider Sells 511 Shares of Stock
www.americanbankingnews.com - February 21 at 9:38 PM
Chris Francis Sells 21,639 Shares of Wave Life Sciences Ltd (WVE) StockChris Francis Sells 21,639 Shares of Wave Life Sciences Ltd (WVE) Stock
www.americanbankingnews.com - February 21 at 9:06 PM
Wave Life Sciences (WVE) Rating Increased to Strong-Buy at BidaskClubWave Life Sciences (WVE) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - February 21 at 7:10 PM
Wave Life Sciences Ltd (WVE) Given Average Rating of "Buy" by BrokeragesWave Life Sciences Ltd (WVE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 5:32 PM
Leerink Swann Raises Wave Life Sciences (WVE) Price Target to $64.00Leerink Swann Raises Wave Life Sciences (WVE) Price Target to $64.00
www.americanbankingnews.com - February 21 at 11:10 AM
Mizuho Reaffirms "Buy" Rating for Wave Life Sciences (WVE)Mizuho Reaffirms "Buy" Rating for Wave Life Sciences (WVE)
www.americanbankingnews.com - February 20 at 8:26 PM
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System DisordersWave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
finance.yahoo.com - February 20 at 9:22 AM
Wave Life Sciences (WVE) Upgraded at BidaskClubWave Life Sciences (WVE) Upgraded at BidaskClub
www.americanbankingnews.com - February 19 at 1:02 PM
Zacks: Brokerages Expect Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $630,000.00Zacks: Brokerages Expect Wave Life Sciences Ltd (WVE) Will Announce Quarterly Sales of $630,000.00
www.americanbankingnews.com - February 16 at 11:06 AM
WVE Crosses Above Average Analyst TargetWVE Crosses Above Average Analyst Target
www.nasdaq.com - February 16 at 9:24 AM
Zacks: Brokerages Anticipate Wave Life Sciences Ltd (WVE) Will Announce Earnings of -$1.00 Per ShareZacks: Brokerages Anticipate Wave Life Sciences Ltd (WVE) Will Announce Earnings of -$1.00 Per Share
www.americanbankingnews.com - February 14 at 3:16 AM
Wave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceWave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:21 PM
Wave Life Sciences (WVE) Cut to Hold at BidaskClubWave Life Sciences (WVE) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 1 at 6:52 AM
Wave Life Sciences Ltd (WVE) Expected to Announce Quarterly Sales of $630,000.00Wave Life Sciences Ltd (WVE) Expected to Announce Quarterly Sales of $630,000.00
www.americanbankingnews.com - January 30 at 8:10 AM
BidaskClub Upgrades Wave Life Sciences (WVE) to "Buy"BidaskClub Upgrades Wave Life Sciences (WVE) to "Buy"
www.americanbankingnews.com - January 27 at 1:12 PM
Form 4 Wave Life Sciences Ltd. For: Jan 23 Filed by: Vargeese ChandraForm 4 Wave Life Sciences Ltd. For: Jan 23 Filed by: Vargeese Chandra
www.streetinsider.com - January 26 at 5:58 AM
Insider Selling: Wave Life Sciences Ltd (WVE) Insider Sells 2,000 Shares of StockInsider Selling: Wave Life Sciences Ltd (WVE) Insider Sells 2,000 Shares of Stock
www.americanbankingnews.com - January 26 at 12:20 AM
Zacks Investment Research Lowers Wave Life Sciences (WVE) to SellZacks Investment Research Lowers Wave Life Sciences (WVE) to Sell
www.americanbankingnews.com - January 13 at 2:42 PM
Zacks: Analysts Anticipate Wave Life Sciences Ltd (WVE) Will Post Quarterly Sales of $630,000.00Zacks: Analysts Anticipate Wave Life Sciences Ltd (WVE) Will Post Quarterly Sales of $630,000.00
www.americanbankingnews.com - January 13 at 2:00 PM

SEC Filings

WAVE Life Sciences (NASDAQ:WVE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

WAVE Life Sciences (NASDAQ:WVE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

WAVE Life Sciences (NASDAQ WVE) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.